Medical Management of Brain Tumor Patients

Neurologic Clinics

Volumn 25, Issue 4, 2007, Pages 1035-1071

  Drappatz, Jan ^a,b   Schiff, David ^c   Kesari, Santosh ^a,b   Norden, Andrew D ^a,b   Wen, Patrick Y ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ANTICONVULSIVE AGENT; ATOVAQUONE; CALCITRIOL; CALCIUM; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; COTRIMOXAZOLE; DALTEPARIN; DAPSONE; ETIRACETAM; FELBAMATE; FOLINIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PENTAMIDINE; PHENOBARBITAL; PHENYTEK; PHENYTOIN; PREGABALIN; PRIMIDONE; PYRIMETHAMINE; SULFAMETHOXAZOLE; TIAGABINE; TOPIRAMATE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VITAMIN D; ZONISAMIDE;

ACNE; ANOREXIA; ATAXIA; AVASCULAR NECROSIS; BEHAVIOR DISORDER; BLOOD DYSCRASIA; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN TUMOR; BUFFALO HUMP; CEREBELLUM DEGENERATION; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE DYSFUNCTION; DEPRESSION; DIABETES MELLITUS; DIFFICULTY CONCENTRATING; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG ERUPTION; DUPUYTREN CONTRACTURE; EDEMA; FATIGUE; FOLIC ACID DEFICIENCY; FROZEN SHOULDER; GASTROINTESTINAL HEMORRHAGE; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPONATREMIA; INTESTINE PERFORATION; LIBIDO; LIVER TOXICITY; LUPUS VULGARIS; LYMPHADENOPATHY; MENTAL CONCENTRATION; MOON FACE; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEUROPATHY; OROPHARYNX CANDIDIASIS; OSTEOMALACIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PURPURA; REVIEW; SEDATION; SEIZURE; SEIZURE EXACERBATION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STRIAE DISTENSAE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREMOR; TRUNCAL OBESITY; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; BRAIN EDEMA; BRAIN NEOPLASMS; COGNITION DISORDERS; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; FATIGUE; HUMANS; MAGNETIC RESONANCE IMAGING; SEIZURES; VENOUS THROMBOEMBOLISM;

EID: 35348967949     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2007.07.015     Document Type: Review

References (234)

1. Wen P.Y., Schiff D., Kesari S., et al. Medical management of patients with brain tumors. J Neurooncol 80 3 (2006) 313-332
2. Hauser W.A., Annegers J.F., and Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34 3 (1993) 453-468
3. Morris H.H., Estes M.L., Gilmore R., et al. Chronic intractable epilepsy as the only symptom of primary brain tumor. Epilepsia 34 6 (1993) 1038-1043
4. Cascino G.D. Epilepsy and brain tumors: implications for treatment. Epilepsia 31 Suppl 3 (1990) S37-S44
5. Herman S.T. Epilepsy after brain insult: targeting epileptogenesis. Neurology 59 9 Suppl. 5 (2002) S21-S26
6. Moots P.L., Maciunas R.J., Eisert D.R., et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52 7 (1995) 717-724
7. Vecht C.J., and van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 67 12 Suppl 4 (2006) S10-S13
8. Bateman D.E., Hardy J.A., McDermott J.R., et al. Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 10 2 (1988) 112-114
9. Wolf H.K., Roos D., Blumcke I., et al. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol (Berl) 91 4 (1996) 376-384
10. Cavaliere R., Farace E., and Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 63 12 (2006) 1746-1749
11. Forsyth P.A., Weaver S., Fulton D., et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30 2 (2003) 106-112
12. Franceschetti S., Binelli S., Casazza M., et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 103 1-2 (1990) 47-51
13. Glantz M.J., Cole B.F., Friedberg M.H., et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46 4 (1996) 985-991
14. Lee S.T., Lui T.N., Chang C.N., et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 31 5 (1989) 361-364
15. North J.B., Penhall R.K., Hanieh A., et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 58 5 (1983) 672-677
16. Sirven J.I., Wingerchuk D.M., Drazkowski J.F., et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 79 12 (2004) 1489-1494
17. Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42 4 (2001) 515-524
18. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 10 (2000) 1886-1893
19. Batchelor T.T., and Byrne T.N. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 20 6 (2006) 1337-1361
20. Chang S.M., Parney I.F., Huang W., et al. Patterns of care for adults with newly diagnosed malignant glioma. Jama 293 5 (2005) 557-564
21. Chalk J.B., Ridgeway K., Brophy T., et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatr 47 10 (1984) 1087-1090
22. Lawson L.A., Blouin R.A., Smith R.B., et al. Phenytoin-dexamethasone interaction: a previously unreported observation. Surg Neurol 16 1 (1981) 23-24
23. Werk Jr. E.E., Choi Y., Sholiton L., et al. Interference in the effect of dexamethasone by diphenylhydantoin. N Engl J Med 281 1 (1969) 32-34
24. Sperling M.R., and Ko J. Seizures and brain tumors. Semin Oncol 33 3 (2006) 333-341
25. Dofferhoff A.S., Berendsen H.H., vd Naalt J., et al. Decreased phenytoin level after carboplatin treatment. Am J Med 89 2 (1990) 247-248
26. Fincham R.W., and Schottelius D.D. Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1 2 (1979) 277-283
27. Grossman S.A., Sheidler V.R., and Gilbert M.R. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87 5 (1989) 505-510
28. Chang T.K., Chen G., and Waxman D.J. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 274 1 (1995) 270-275
29. Prados M.D., Yung W.K., Jaeckle K.A., et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 6 1 (2004) 44-54
30. Vecht C.J., Wagner G.L., and Wilms E.B. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2 7 (2003) 404-409
31. Cloughesy T.F., Wen P.Y., Robins H.I., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24 22 (2006) 3651-3656
32. Prados M.D., Lamborn K., Yung W.K., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 8 2 (2006) 189-193
33. Prados M.D., Lamborn K.R., Chang S., et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 8 1 (2006) 67-78
34. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12 16 (2006) 4899-4907
35. McCune J.S., Hawke R.L., LeCluyse E.L., et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68 4 (2000) 356-366
36. Gupta E., Wang X., Ramirez J., et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39 5 (1997) 440-444
37. Camphausen K., Cerna D., Scott T., et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114 3 (2005) 380-386
38. Cascino G.D. Surgical treatment for epilepsy. Epilepsy Res 60 2-3 (2004) 179-186
39. Fishman R.A. Brain edema. N Engl J Med 293 14 (1975) 706-711
40. Papadopoulos M.C., Saadoun S., Binder D.K., et al. Molecular mechanisms of brain tumor edema. Neuroscience 129 4 (2004) 1011-1020
41. Janzer R.C., and Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325 6101 (1987) 253-257
42. Bates D.O., Lodwick D., and Williams B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 6 2 (1999) 83-96
43. Machein M.R., and Plate K.H. VEGF in brain tumors. J Neurooncol 50 1-2 (2000) 109-120
44. Lamszus K., Lengler U., Schmidt N.O., et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46 4 (2000) 938-947 [discussion: 938-47]
45. Arrieta O., Garcia E., Guevara P., et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94 12 (2002) 3210-3218
46. Behzadian M.A., Windsor L.J., Ghaly N., et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. Faseb J 17 6 (2003) 752-754
47. Wang W., Dentler W.L., and Borchardt R.T. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 280 1 (2001) H434-H440
48. Wang F., Feng X.C., Li Y.M., et al. Aquaporins as potential drug targets. Acta Pharmacol Sin 27 4 (2006) 395-401
49. Ludwig H.C., Feiz-Erfan I., Bockermann V., et al. Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas. Anticancer Res 20 1A (2000) 299-304
50. Lafuente J.V., Adan B., Alkiza K., et al. Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci 13 1-2 (1999) 177-185
51. Ludwig H.C., Ahkavan-Shigari R., Rausch S., et al. Oedema extension in cerebral metastasis and correlation with the expression of nitric oxide synthase isozymes (NOS I-III). Anticancer Res 20 1A (2000) 305-310
52. Plate K.H., Breier G., and Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4 3 (1994) 207-218
53. Ingraham F.D., Matson D.D., and Mc L.R. Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. N Engl J Med 246 15 (1952) 568-571
54. Galicich J.H., French L.A., and Melby J.C. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet 81 (1961) 46-53
55. French L.A., and Galicich J.H. The use of steroids for control of cerebral edema. Clin Neurosurg 10 (1964) 212-223
56. Romero I.A., Radewicz K., Jubin E., et al. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett 344 2 (2003) 112-116
57. Batchelor T., and DeAngelis L.M. Medical management of cerebral metastases. Neurosurg Clin N Am 7 3 (1996) 435-446
58. Vecht C.J., Hovestadt A., Verbiest H.B., et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44 4 (1994) 675-680
59. Vick N.A., and Wilson C.B. Total care of the patient with a brain tumor with consideration of some ethical issues. Neurol Clin 3 4 (1985) 705-710
60. Zaki H.S., Jenkinson M.D., Du Plessis D.G., et al. Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir (Wien) 146 8 (2004) 841-845
61. Bastin M.E., Carpenter T.K., Armitage P.A., et al. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol 27 2 (2006) 402-408
62. Lu S., Ahn D., Johnson G., et al. Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. AJNR Am J Neuroradiol 24 5 (2003) 937-941
63. Rabinstein A.A. Treatment of cerebral edema. Neurologist 12 2 (2006) 59-73
64. Gomes J.A., Stevens R.D., Lewin III J.J., et al. Glucocorticoid therapy in neurologic critical care. Crit Care Med 33 6 (2005) 1214-1224
65. Gattis W.A., and May D.B. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann Pharmacother 30 5 (1996) 520-526
66. Afifi A.K., Bergman R.A., and Harvey J.C. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 123 4 (1968) 158-173
67. Adachi J.D., Bensen W.G., and Cividino A. Corticosteroid-induced osteoporosis. J Am Med Womens Assoc 53 1 (1998) 25-30 40
68. Gebhard K.L., and Maibach H.I. Relationship between systemic corticosteroids and osteonecrosis. Am J Clin Dermatol 2 6 (2001) 377-388
69. Rizza R.A., Mandarino L.J., and Gerich J.E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54 1 (1982) 131-138
70. Brunner R., Schaefer D., Hess K., et al. Effect of high-dose cortisol on memory functions. Ann N Y Acad Sci 1071 (2006) 434-437
71. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 9 (1991) 735-740
72. Warshaw A.L., Welch J.P., and Ottinger L.W. Acute perforation of the colon associated with chronic corticosteroid therapy. Am J Surg 131 4 (1976) 442-446
73. Davies A.N., Brailsford S., and Beighton D. Corticosteroids and oral candidosis. Palliat Med 15 6 (2001) 521
74. Stuck A.E., Minder C.E., and Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11 6 (1989) 954-963
75. Weissman D.E., Dufer D., Vogel V., et al. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 5 2 (1987) 125-128
76. Marcus P., and McCauley D.L. Steroid therapy and H2-receptor antagonists: pharmacoeconomic implications. Clin Pharmacol Ther 61 5 (1997) 503-508
77. Spiro H.M. Is the steroid ulcer a myth?. N Engl J Med 309 1 (1983) 45-47
78. Carson J.L., Strom B.L., Schinnar R., et al. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 91 3 (1991) 223-228
79. Batchelor T.T., Taylor L.P., Thaler H.T., et al. Steroid myopathy in cancer patients. Neurology 48 5 (1997) 1234-1238
80. Dropcho E.J., and Soong S.J. Steroid-induced weakness in patients with primary brain tumors. Neurology 41 8 (1991) 1235-1239
81. Hanson P., Dive A., Brucher J.M., et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 20 11 (1997) 1371-1380
82. van Balkom R.H., van der Heijden H.F., van Herwaarden C.L., et al. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med 45 3 (1994) 114-122
83. Owczarek J., Jasinska M., and Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57 1 (2005) 23-34
84. Hickson R.C., Czerwinski S.M., and Wegrzyn L.E. Glutamine prevents downregulation of myosin heavy chain synthesis and muscle atrophy from glucocorticoids. Am J Physiol 268 4 Pt 1 (1995) E730-E734
85. Gayan-Ramirez G., Vanderhoydonc F., Verhoeven G., et al. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 159 1 (1999) 283-289
86. Singleton J.R., Baker B.L., and Thorburn A. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 141 8 (2000) 2945-2950
87. Stern L.Z., Gruener R., and Amundsen P. Diphenylhydantoin for steroid-induced muscle weakness. Jama 223 11 (1973) 1287-1288
88. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13 10 (2002) 777-787
89. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 6 (2000) 993-1000
90. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 2 (1998) 274-282
91. Homik J., Cranney A., Shea B., et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2 (2000) CD001347
92. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44 7 (2001) 1496-1503
93. Gourlay M., Franceschini N., and Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol 26 2 (2007) 144-153
94. Tascioglu F., Colak O., Armagan O., et al. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int 26 1 (2005) 21-29
95. Lane N.E., Sanchez S., Modin G.W., et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15 5 (2000) 944-951
96. Lavelle W., Carl A., Lavelle E.D., et al. Vertebroplasty and kyphoplasty. Med Clin North Am 91 2 (2007) 299-314
97. Lewis D.A., and Smith R.E. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 5 4 (1983) 319-332
98. Warrington T.P., and Bostwick J.M. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81 10 (2006) 1361-1367
99. Wada K., Yamada N., Sato T., et al. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics 42 6 (2001) 461-466
100. Hall R.C., Popkin M.K., Stickney S.K., et al. Presentation of the steroid psychoses. J Nerv Ment Dis 167 4 (1979) 229-236
101. Lupien S.J., and McEwen B.S. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev 24 1 (1997) 1-27
102. Drug-induced convulsions. Report from Boston Collaborative Drug Surveillance Program. Lancet 2 7779 (1972) 677-679
103. Stiefel F.C., Breitbart W.S., and Holland J.C. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 7 5 (1989) 479-491
104. Edman J.C., Kovacs J.A., Masur H., et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 334 6182 (1988) 519-522
105. Thomas Jr. C.F., and Limper A.H. Pneumocystis pneumonia. N Engl J Med 350 24 (2004) 2487-2498
106. Kovacs J.A., Gill V.J., Meshnick S., et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. Jama 286 19 (2001) 2450-2460
107. Henson J.W., Jalaj J.K., Walker R.W., et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 48 4 (1991) 406-409
108. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 27 3 (1996) 235-240
109. Slivka A., Wen P.Y., Shea W.M., et al. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 94 2 (1993) 216-219
110. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 5 (2002) 1375-1382
111. Cohen M.H., Johnson J.R., and Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11 19 Pt 1 (2005) 6767-6771
112. Clancey J.K. Spinal epidural lipomatosis: a case study. J Neurosci Nurs 36 4 (2004) 208-209 213
113. Zampella E.J., Duvall E.R., Sekar B.C., et al. Symptomatic spinal epidural lipomatosis as a complication of steroid immunosuppression in cardiac transplant patients. Report of two cases. J Neurosurg 67 5 (1987) 760-764
114. Smith C.L. "Corticosteroid glaucoma" a summary and review of the literaure. Am J Med Sci 252 2 (1966) 239-244
115. Sundmark E. The occurrence of posterior subcapsular cataracts in patients on long-term systemic corticosteroid therapy. Acta Ophthalmol (Copenh) 41 (1963) 515-523
116. Black R.L., Oglesby R.B., Von Sallmann L., et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. Jama 174 (1960) 166-171
117. Hadjikoutis S., Morgan J.E., Wild J.M., et al. Ocular complications of neurological therapy. Eur J Neurol 12 7 (2005) 499-507
118. Cersosimo R.J., and Brophy M.T. Hiccups with high dose dexamethasone administration: a case report. Cancer 82 2 (1998) 412-414
119. Lewis J.H. Hiccups: causes and cures. J Clin Gastroenterol 7 6 (1985) 539-552
120. Braithwaite S.S., Barr W.G., Rahman A., et al. How to avoid metabolic emergencies. Postgrad Med 104 5 (1998) 163-166 171, 175-66
121. Rotstein J., and Good R.A. Steroid pseudorheumatism. AMA Arch Intern Med 99 4 (1957) 545-555
122. Villalona-Calero M.A., Eckardt J., Burris H., et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 9 1 (1998) 71-77
123. Tjuvajev J., Uehara H., Desai R., et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 56 6 (1996) 1352-1360
124. Badie B., Schartner J.M., Hagar A.R., et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin Cancer Res 9 2 (2003) 872-877
125. Khan R.B., Krasin M.J., Kasow K., et al. Cyclooxygenase-2 inhibition to treat radiation-induced brain necrosis and edema. J Pediatr Hematol Oncol 26 4 (2004) 253-255
126. Portnow J., Suleman S., Grossman S.A., et al. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro-oncol 4 1 (2002) 22-25
127. Josko J., and Knefel K. The role of vascular endothelial growth factor in cerebral oedema formation. Folia Neuropathol 41 3 (2003) 161-166
128. Gonzalez J., Kumar A.J., Conrad C.A., et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67 2 (2007) 323-326
129. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cells 11 1 (2007) 83-95
130. Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm 62 22 Suppl 5 (2005) S4-S6
131. Constantini S., Kornowski R., Pomeranz S., et al. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir (Wien) 109 3-4 (1991) 93-97
132. Ruff R.L., and Posner J.B. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 13 3 (1983) 334-336
133. Sawaya R., Zuccarello M., Elkalliny M., et al. Postoperative venous thromboembolism guganand brain tumors: Part I. Clinical profile. J Neurooncol 14 2 (1992) 119-125
134. Simanek R., Vormittag R., Hassler M., et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro-oncol 9 2 (2007) 89-95
135. Brandes A.A., Scelzi E., Salmistraro G., et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33 10 (1997) 1592-1596
136. Cheruku R., Tapazoglou E., Ensley J., et al. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68 12 (1991) 2621-2624
137. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 5 (1999) 285-291
138. Marras L.C., Geerts W.H., and Perry J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89 3 (2000) 640-646
139. Sciacca F.L., Ciusani E., Silvani A., et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 10 4 (2004) 1312-1317
140. Tabori U., Beni-Adani L., Dvir R., et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 43 6 (2004) 633-636
141. Alpert J.S., and Dalen J.E. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 36 6 (1994) 417-422
142. Horlander K.T., Mannino D.M., and Leeper K.V. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163 14 (Jul 28 2003) 1711-1717
143. Goldhaber S.Z., Visani L., and De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353 9162 (1999) 1386-1389
144. Naess I.A., Christiansen S.C., Romundstad P., et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5 4 (2007) 692-699
145. Gerber D.E., Grossman S.A., and Streiff M.B. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24 8 (2006) 1310-1318
146. Walsh D.C., and Kakkar A.K. Thromboembolism in brain tumors. Curr Opin Pulm Med 7 5 (2001) 326-331
147. Thoron L., and Arbit E. Hemostatic changes in patients with brain tumors. J Neurooncol 22 2 (1994) 87-100
148. Hamada K., Kuratsu J., Saitoh Y., et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77 9 (1996) 1877-1883
149. Iberti T.J., Miller M., Abalos A., et al. Abnormal coagulation profile in brain tumor patients during surgery. Neurosurgery 34 3 (1994) 389-394 [discussion: 385-94]
150. Sawaya R., and Highsmith R.F. Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile. J Neurooncol 14 2 (1992) 113-118
151. McRae S.J., and Ginsberg J.S. Update in the diagnosis of deep-vein thrombosis and pulmonary embolism. Curr Opin Anaesthesiol 19 1 (2006) 44-51
152. Segal J.B., Eng J., Tamariz L.J., et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med 5 1 (2007) 63-73
153. Bates S.M., and Ginsberg J.S. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 351 3 (2004) 268-277
154. Palareti G., Cosmi B., and Legnani C. Diagnosis of deep vein thrombosis. Semin Thromb Hemost 32 7 (2006) 659-672
155. Wells P.S., Anderson D.R., Rodger M., et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349 13 (2003) 1227-1235
156. Qaseem A., Snow V., Barry P., et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med 5 1 (2007) 57-62
157. Rathbun S.W., Raskob G.E., and Whitsett T.L. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med 132 3 (2000) 227-232
158. Quiroz R., Kucher N., Zou K.H., et al. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. Jama 293 16 (2005) 2012-2017
159. Roy P.M., Colombet I., Durieux P., et al. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. Bmj 331 7511 (2005) 259
160. Stein P.D., Fowler S.E., Goodman L.R., et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 354 22 (2006) 2317-2327
161. Bostrom S., Holmgren E., Jonsson O., et al. Post-operative thromboembolism in neurosurgery. A study on the prophylactic effect of calf muscle stimulation plus dextran compared to low-dose heparin. Acta Neurochir (Wien) 80 3-4 (1986) 83-89
162. Bucci M.N., Papadopoulos S.M., Chen J.C., et al. Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: a randomized trial. Surg Neurol 32 4 (1989) 285-288
163. Skillman J.J., Collins R.E., Coe N.P., et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery 83 3 (1978) 354-358
164. Turpie A.G., Hirsh J., Gent M., et al. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 149 3 (1989) 679-681
165. Chan A.T., Atiemo A., Diran L.K., et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis 8 2 (1999) 139-142
166. Flinn W.R., Sandager G.P., Silva Jr. M.B., et al. Prospective surveillance for perioperative venous thrombosis. Experience in 2643 patients. Arch Surg 131 5 (May 1996) 472-480
167. Agnelli G., Piovella F., Buoncristiani P., et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339 2 (1998) 80-85
168. Cerrato D., Ariano C., and Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg 49 3 (1978) 378-381
169. Comerota A.J., Chouhan V., Harada R.N., et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 226 3 (1997) 306-313 [discussion: 304-13]
170. Iorio A., and Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 160 15 (2000) 2327-2332
171. Carman T.L., Kanner A.A., Barnett G.H., et al. Prevention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J 96 1 (2003) 17-22
172. Stephens P.H., Healy M.T., Smith M., et al. Prophylaxis against thromboembolism in neurosurgical patients: a survey of current practice in the United Kingdom. Br J Neurosurg 9 2 (1995) 159-163
173. Perry J.R., Rogers L., Laperriere N., et al. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol 25 18S (2007) 2011
174. Rocha E., Martinez-Gonzalez M.A., Montes R., et al. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 85 9 (2000) 935-942
175. Mismetti P., Laporte S., Darmon J.Y., et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88 7 (2001) 913-930
176. Levin J.M., Schiff D., Loeffler J.S., et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 43 6 (1993) 1111-1114
177. Schiff D., and DeAngelis L.M. Therapy of venous thromboembolism in patients with brain metastases. Cancer 73 2 (1994) 493-498
178. Olin J.W., Young J.R., Graor R.A., et al. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?. Arch Intern Med 147 12 (1987) 2177-2179
179. Choucair A.K., Silver P., and Levin V.A. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 66 3 (1987) 357-358
180. Quevedo J.F., Buckner J.C., Schmidt J.L., et al. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 69 4 (1994) 329-332
181. Ruff R.L., and Posner J.B. The incidence of systemic venous thrombosis and the risk of anticoagulation in patients with malignant gliomas. Trans Am Neurol Assoc 106 (1981) 223-226
182. Pruitt A.A. Treatment of medical complications in patients with brain tumors. Curr Treat Options Neurol 7 4 (2005) 323-336
183. Knovich M.A., and Lesser G.J. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol 5 6 (2004) 511-517
184. Norris L.K., and Grossman S.A. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol 22 2 (1994) 127-137
185. Wen P.Y., and Marks P.W. Medical management of patients with brain tumors. Curr Opin Oncol 14 3 (2002) 299-307
186. Coon W.W., and Willis III P.W. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 133 3 (1974) 386-392
187. Levine M.N., Raskob G., Beyth R.J., et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 287S-310S
188. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 1 Suppl (2001) 64S-94S
189. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 15 (2002) 1729-1735
190. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (2003) 146-153
191. Wakelee H.A., and Sikic B.I. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clin Lung Cancer 7 Suppl 1 (2005) S6-S12
192. Monreal M., Zacharski L., Jimenez J.A., et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2 8 (2004) 1311-1315
193. Linenberger M.L., and Wittkowsky A.K. Thromboembolic complications of malignancy. Part 2: management. Oncology (Williston Park) 19 8 (2005) 1077-1084 [discussion: 1084, 1078-87]
194. Dunn A.S., and Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 106 6 (1999) 660-669
195. Koopman M.M., Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334 11 (1996) 682-687
196. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 11 (1996) 677-681
197. Kovacs M.J., Anderson D., Morrow B., et al. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 83 2 (2000) 209-211
198. Crowther M.A., Berry L.R., Monagle P.T., et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116 1 (2002) 178-186
199. Warkentin T.E., and Crowther M.A. Reversing anticoagulants both old and new. Can J Anaesth 49 6 (2002) S11-S25
200. Aguilar M.I., Hart R.G., Kase C.S., et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82 1 (2007) 82-92
201. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 119 5 (2007) 643-651
202. Ingerslev J., Vanek T., and Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 53 1 (2007) 17-22
203. Firozvi K., Deveras R.A., and Kessler C.M. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 81 8 (2006) 582-589
204. Gerotziafas G.T., Depasse F., Chakroun T., et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 91 3 (2004) 531-537
205. Heimans J.J., and Taphoorn M.J. Impact of brain tumour treatment on quality of life. J Neurol 249 8 (2002) 955-960
206. Pelletier G., Verhoef M.J., Khatri N., et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 57 1 (2002) 41-49
207. Osoba D., Aaronson N.K., Muller M., et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 34 3 (1997) 263-278
208. Osoba D., Brada M., Prados M.D., et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncol 2 4 (2000) 221-228
209. Salo J., Niemela A., Joukamaa M., et al. Effect of brain tumour laterality on patients' perceived quality of life. J Neurol Neurosurg Psychiatry 72 3 (2002) 373-377
210. Hickok J.T., Roscoe J.A., Morrow G.R., et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer 104 8 (2005) 1772-1778
211. Lovely M.P., Miaskowski C., and Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum 26 5 (1999) 921-925
212. Rogers M.P., Orav J., and Black P.M. The use of a simple Likert scale to measure quality of life in brain tumor patients. J Neurooncol 55 2 (2001) 121-131
213. Brown P.D., Ballman K.V., Rummans T.A., et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 76 3 (2006) 283-291
214. Carter G.T., Weiss M.D., Lou J.S., et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 22 1 (2005) 55-59
215. Fishbain D.A., Cutler R.B., Lewis J., et al. Modafinil for the treatment of pain-associated fatigue: review and case report. J Pain Palliat Care Pharmacother 18 2 (2004) 39-47
216. Kraft G.H., and Bowen J. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 65 12 (2005) 1995-1997 [author reply: 1995-7]
217. Rabkin J.G., McElhiney M.C., Rabkin R., et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 65 12 (2004) 1688-1695
218. Rammohan K.W., and Lynn D.J. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 65 12 (2005) 1995-1997 [author reply: 1995-7]
219. Schwartz T.L., Azhar N., Cole K., et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 65 9 (2004) 1223-1227
220. Sevy S., Rosenthal M.H., Alvir J., et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66 7 (2005) 839-843
221. Stankoff B., Waubant E., Confavreux C., et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 64 7 (2005) 1139-1143
222. Zifko U.A., Rupp M., Schwarz S., et al. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249 8 (2002) 983-987
223. Ashton A.K. Modafinil augmentation of phenelzine for residual fatigue in dysthymia. Am J Psychiatry 161 9 (2004) 1716-1717
224. DeBattista C., Lembke A., Solvason H.B., et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 24 1 (2004) 87-90
225. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. J Affect Disord 81 2 (2004) 173-178
226. Price C.S., and Taylor F.B. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety 21 4 (2005) 149-153
227. Kaleita T.A., Wellisch D.K., Graham C.A., et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol 24 18S (2006) 1503 [abstract]
228. Wefel J.S., Kayl A.E., and Meyers C.A. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 90 9 (2004) 1691-1696
229. Correa D.D. Cognitive functions in brain tumor patients. Hematol Oncol Clin North Am 20 6 (2006) 1363-1376
230. Meyers C.A., Weitzner M.A., Valentine A.D., et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16 7 (1998) 2522-2527
231. Shaw E.G., Rosdhal R., D'Agostino Jr. R.B., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24 9 (2006) 1415-1420
232. Lee M.A., Leng M.E., and Tiernan E.J. Risperidone: a useful adjunct for behavioural disturbance in primary cerebral tumours. Palliat Med 15 3 (2001) 255-256
233. Thiessen B., and DeAngelis L.M. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol 55 5 (1998) 705-710
234. Litofsky N.S., Farace E., Anderson Jr. F., et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54 2 (2004) 358-366 [discussion: 357-66]